

ATMP Sweden

Annual report 2024

September 2024

Content

1. ATMP landscape overview and developments
2. Company landscape
3. Research and publications
4. ATMP in healthcare
5. Clinical trials and horizon scanning
6. Job opportunity analysis
7. Appendix

Executive summary

Since 2018, the ATMP field in Sweden has witnessed substantial progress with a rapidly evolving infrastructure, clinical activity and industrial landscape

- An **expanding infrastructure** including today's 4 ATMP centers and numerous ATMP initiatives both on national and regional level
- **25 SME ATMP Developers** in Sweden, **+4 new companies** from 2018
- **+183% growth employees** among SME ATMP developers (+220 employees)
- **48 active ATMP clinical trials** in Sweden, 14 Ph III
- **7 ATMPs recommended** by NT-rådet
- **6 ATMPs** currently investigated by TLV
- **High research activity** and increasing number of publications
- On a global level, there are **+1700 active ATMP clinical trials**, including almost **100 in phase III**

Since 2018, the ATMP field in Sweden has witnessed substantial progress with a rapidly evolving infrastructure and clinical use

ATMP development in Sweden (2018-2024*)

4

ATMP centres inaugurated

39

Started clinical ATMP trials (2018 – 2024*)

4

New ATMP SME Developers in Sweden

10+

Active ATMP related initiatives in Sweden

Samlat engagemang för fler kliniska studier inom ATMP till Sverige och Västra Götaland



Drottning Silvias barnsjukhus startar Nordens första barncentrum för ATMP

Källa: Sahlgrenska Universitetssjukhuset

11 jan 2024

Avancerade terapier, ATMP, är något som håller på att revolutionera möjligheterna att behandla allvarliga sjukdomar. Nu startar Drottning Silvias barnsjukhus Nordens första och enda barncentrum för ATMP samtidigt som sjukvården och akademien stärker sitt samarbete.



All news

Talk to us

Vinnova supports the formation of a Nordic CCRM hub

Regioner satsar på ATMP

Regioner med universitetssjukhus satsar alltmer på att bygga upp ATMP och för att samla klinisk och akademisk forskning kring avancerade beh

Vid ett möte i Lund diskuterades de stora ambitioner Region Skåne har inom områ

Måndag 29 januari 2024

Framtidens medicin



Lund bygger dubbla ATMP-centrum

Intresset för ATMP, läkemedel för avancerad terapi, växer stort. I Sverige offentliggjordes 2023 större satsningar vid lärosäten och sjukhus i Stockholm, Uppsala och Skåne. I Lund bygger universitetet och regionen inte bara ett centrum utan varsitt, som ska samarbeta.



Foto: Abock

Nu har även Uppsala fått ett ATMP-centrum

Sök till nya National ATMP Research School!

Av Agata Garpenlind - publicerad 18 januari 2024

10-year anniversary of CAR T cell[®] treatment in Europe

2024-05-13

Milestone celebrated Monday the 13th of May, 2024 at Uppsala Castle

On May 13th 2014, the first chimeric antigen receptor (CAR) T cell treatment in Europe was administered to a lymphoma patient as part of a clinical trial[®] at Uppsala University Hospital (EudraCT[®] No: 2013-001393-19). The trial was a collaboration between Uppsala University, Uppsala University Hospital and Baylor College of Medicine in Houston, Texas. 15 patients were treated in the first study, that was soon followed by a second study with the same CD19-targeting CAR T cell[®] product at Uppsala University Hospital in 2017. 10 years to the day, this milestone will be celebrated with a program reflecting on the first treatment and developments over the last 10 years.



First infusion of European CAR T

CAR T cells is an immunotherapy[®] that uses the ability of a patient's own immune system, or more specifically T cells, to recognize and kill endogenous cells that have become infected with viruses or transformed into tumour cells. The medicine is produced by patient donating a slightly larger blood sample from which T cells are purified. These cells are then genetically modified to express a new protein on the cell surface – called a chimeric antigen receptor (CAR). This receptor consists of an antibody part (which recognizes the tumour) and parts of the T cell receptor (the receptor by which T cells normally recognize their targets). The cells are then given back to the patient where they seek out the tumour[®] cells in the patient's body and kill them.

Monday the 13th of May, 2024, at Uppsala Castle Gunilla Enblad, Angelica Loskog, Hans Hanberg, Hanna Karlsson and Margareta Kutz will share their experiences from involvement in

Note: *2024 as by September 2024. Initiatives including e.g. CAMP, NextGenNK, SweCARNET, Genenova, Indicell, ATMP national hospital center network, National ATMP PhD School. Full list available at ATMP Sweden website.










ATMP2030

ATMP2030 in short

- The ATMP2030 project was established in 2019, as one of several initiatives under ATMP Sweden
- The project aims to establish a 'Vision Driven Innovation Milieu' for long-term transformation of the systems required for successful development and implementation of advanced therapy gene and cell therapeutic products, Advanced Therapy Medicinal Products (ATMP)
- Expected effects following the project are that Swedish healthcare and patients can access the developments within ATMP and make Sweden more attractive for future investments in the area

Subgoals of ATMP 2030

-  National coordination and strengthening of the network, as well as increased international contacts and collaborations
-  Increased capacity for industrial development and manufacture of ATMPs in Sweden
-  Effective processes for availability of cost-effective ATMPs within Swedish healthcare
-  Increase knowledge and secure future competence needs
-  Organization and financing model for sustainable continuation

Partners to ATMP2030

VINNOVA

KAROLINSKA
UNIVERSITETSSJUKHUSET

AKADEMISKA
SJUKHUSET

VÄSTRA
GÖTALANDSREGIONEN

region
västerbotten

Region
Östergötland

Region
Örebro län

RI
SE

Lif De forskande
Läkemedelsföretagen

AstraZeneca

SKÅNE

CombiGene

KAROLINSKA
INSTITUTET

VERIGRAFT

LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Apotekarsocieteten
Swedish Pharmaceutical Society

Läkemedelsakademin
Swedish Academy of Pharmaceutical Sciences

triathlon
triathlon group

KAROLINSKA
INSTITUTET


nextcell
pharma

U ME Å
UNIVERSITET


Content

1. ATMP landscape overview and developments
2. Company landscape
3. Research and publications
4. ATMP in healthcare
5. Clinical trials and horizon scanning
6. Job opportunity analysis
7. Appendix

The Swedish ATMP landscape – a multi-cluster landscape with strong links across the regions



An expanding ATMP ecosystem in the Nordics




Note: SME ATMP companies active as of dec 2023

Source: Triathlon analysis, Danish CAR-T cell Network ([link](#)), Center for Gene and Cellular Therapy Aarhus University Hospital ([link](#)), DASCS ([link](#))

Selected highlights of ATMP field in Sweden 2018 to 2024 show many important events over the years

- **ATMP Sweden** started
- **Testa Center** opened
- **CAMP** (Centre for Advanced Medicinal Products) – an ATMP Sweden initiative started
- **Karolinska University Hospital and KI** opened first Swedish **Comprehensive Cancer Centre**
- **Sahlgrenska ATMP center** inaugurated
- **NextGenNK** – an ATMP Sweden initiative started
- **ATMP2030** entered second phase
- Creation of **ATMP center network**
- Report on **ATMP education and future competence needs** released
- **Advanced Cell and Gene therapies for Children center** opened in Sahlgrenska
- **Genomic Medicine Sweden (GMS)** received **49 MSEK** for research related to precision medicine
- **Coordination function** for ATMP inaugurated



A vibrant and diverse ATMP industrial landscape




Note: As of June 2024, with SME ATMP companies active as of dec 2023. International Pharma are companies related to ATMP that have at least an office in Sweden. Ribocure Pharmaceuticals is not ATMP per se but is closely linked with its RNA therapies
 Source: Triathlon analysis

Development of clinical ATMP trials in Sweden

Cumulative # started clinical ATMP trials in Sweden 2006 to 2024*


Based on start year for currently active trials




Note: *2024 as per 18th of September. Studies categorized as only FIH in data sorted as phase I. Study from Intellia Therapeutics with no provided clinical phase in data.
Source: Triathlon analysis based on clinical trials data received from ATMP centres on [ATMPSweden.se](https://atmpsweden.se) ([link](#)).

Significant increase of number of CAR-T treatments since the first at Uppsala University Hospital* in 2014

Total number of CAR-T infusions (2022-2024**)



Development of CAR-T treatment 2014-2024



Note: *Uppsala University Hospital was the first hospital in Europe to give CAR-T treatment. Treatment was produced by Vecura at Karolinska University Hospital. **2024 as per 31 of May. Data for 2022 and 2023 retrieved from November of these years.

Source: Triathlon analysis based on SWECARNET CART/TCR treatments data ([link](#))

Content

1. ATMP landscape overview and developments
2. Company landscape
3. Research and publications
4. ATMP in healthcare
5. Clinical trials and horizon scanning
6. Job opportunity analysis
7. Appendix

Company landscape


Selected highlights

- 25 SME ATMP developers in Sweden, 4 new since 2018
- Swedish ATMP developers are spread across the country with most SME developers found in Stockholm, followed by Lund/Skåne
- 311 employees were reported for Swedish SME ATMP developers in 2022
- From 2018 to 2022, there was an 183% increase in employees for ATMP SME developers in Sweden
- Sweden makes up the majority of SME developers in the Nordic countries with 25 out of 46 companies
- A multitude of international pharmaceutical companies have presence at some level in the Nordics
- 15 out of 25 Swedish SME developers have their research focus area on sCTMP, followed by GTMP with 8 companies




The ATMP SME developer field in Sweden is growing

of employees of SME drug developer companies




of SME drug developer companies



Note: *Idogen filed for bankruptcy in 2023 and Cell4Cure was created and acquired Idogen's technology platform in the end of 2023. Number of employees as per direct employees in Swedish AB, i.e. not taking into account e.g. consultants. Only companies regarded as active in dec 2023 were used for data collection, i.e. company data from Idogen was not used for employee count. Source: Triathlon analysis, Business Retriever


SME ATMP developers experienced high employee growth 2018-2022, collectively adding 201 employees

Employee growth per company



Note: Number of employees as per direct employees in Swedish AB, i.e. not taking into account e.g. consultants.
Source: Triathlon analysis, Business Retriever

Out of 46 identified Nordic SME ATMP developers, 54% are located in Sweden




Note: SME ATMP companies active as of dec 2023
Source: Triathlon analysis


Several international companies with ATMP-related R&D have R&D and/or marketing activities in the Nordics



Swedish ATMP SME developers are divided across the country, with a majority of companies in Stockholm



sCTMP is the leading focus area of ATMP SME developers in Sweden; 15 of 25 companies develops sCTMP




Note: Tikomed has 2 reported focus areas, sCTMP and TEP, and was therefore added twice. Categorization for Cellavos, Curacell, Cell4Cure and Sequire estimated based on descriptions on company websites


Source: Triathlon analysis, based on categorization from ATMPSweden website and company websites

Important support functions for ATMP developers are covered by the widespread service and product providers in Sweden

Product providers












Service providers



Note: The total number of companies does not correspond to the number of companies per area as some companies are reported numerous times, due to them having various capabilities.
 CCRM Nordic added as a Manufacture/CMO and TestaCenter as an Analytics/CRO company
 Source: Triathlon analysis, based on categorization from ATMPSweden website

Swedish SMEs ATMP developers have received 20+ MEUR in funding from EU Funding programs

Identified Swedish ATMP SMEs that received funding from the European Commission


| SME | Project | Program | Project timeline | Funding received by program |
|--------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------------|-----------------------------|
|  NEOGAP | Innovative approach to an individualized T-Cell immunotherapy for cancer using Personalized Tumor Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement | Horizon | n/a | 8 119 920 € |
|  CombiGene | A novel gene therapy for epilepsy | Horizon 2020 | 2018–2021 | 3 361 348 € |
|  ILYA PHARMA | Wound healing ILYA-style | Horizon 2020 | 2018–2019 | 2 992 575 € |
|  elicera | iTANK: a universal technology to boost the efficacy of CAR T cell therapies by inducing dual mode-of-action | Horizon | n/a | 2 500 000 € |
|  VERIGRAFT | Personalized Tissue-Engineered Veins as the first Cure for Patients with Chronic Venous Insufficiency | Horizon 2020 | 2017–2019 | 2 184 604 € |
|  ILYA PHARMA | Wound healing ILYA-style 2; Proprietary dressings for the treatment of chronic wounds | Horizon 2020 | 2020–2023 | 1 360 362 € |
|  asgard THERAPEUTICS | TrojanDC - A BREAKTHROUGH DEEP-TECH INNOVATION FOR CANCER IMMUNOTHERAPY (TrojanDC) | Horizon | 2023-2024 | 75 000 € |
|  Sinfonia Biotherapeutics | Tailored cell-based therapies for frontotemporal dementia and related genetically defined CNS orphan indications | Horizon 2020 | 2018–2019 | 50 000€ |
|  asgard THERAPEUTICS | TrojanDC; A Trojan horse rolls into tumour cells, inciting treason | Horizon 2020 | 2019–2020 | 50 000€ |

Note: Based on searches for the identified Swedish SMEs. In the EIC Accelerator database under area “Health”, it was noted that Sweden was among the top 5 EISMEA funding receiving countries.
Source: Triathlon analysis, based on data in EISMEA database and EU Funding & Tenders Portal ([link](#))



The global ATMP funding of 2023 was ~10 BUSD, with only 8% raised in Europe

Total deal values of 2023 in ATMP field



A total of **9.98 BUSD** was raised as **capital** in 2023 in the field of regenerative medicine



1.66 BUSD was raised through **strategic alliances**, more specifically **partnerships** and **licensing agreements**



Majority of funding was raised in North America (74%). **8% of funding was raised in Europe**

Content

1. ATMP landscape overview and developments
2. Company landscape
3. Research and publications
4. ATMP in healthcare
5. Clinical trials and horizon scanning
6. Job opportunity analysis
7. Appendix

Publications

Selected highlights


- Steady growth of number of ATMP related publications for 10 selected European countries (EU10*) since 2009, peaking in 2021 with 5 064 publications
- With 20,5 publications per capita, Sweden had the highest publication productivity among EU10 in 2023
- UK holds the majority of ATMP publications between 2009-2024, followed by Germany and Italy
- Sweden had a 42% increase in annual ATMP related publications from 2020 to 2022, going from 189 to 268
- CAR-T related publications in Sweden have increased with +350% between 2023 and 2018, going from 10 to 46 annual publications

*Germany, UK, France, Spain, Italy, Netherlands and the Nordics




Steady growth of number of publications within ATMP in EU10* since 2009, with a peak in 2021

Total number of publications per year, per country**




Publication productivity per million inhabitants (as of 2024)



Note: *EU10 covers Scandinavia and top 6 countries in terms of number of publications in Europe. **Publications can have collaborating authors in multiple countries – sum of total publications will not be equivalent to total for all countries. For searches boolean search string was used, see details in appendix.
Source: Web of Science

UK is a leading country in EU10* in terms of publications** in the ATMP field between 2009-2024

Total published research articles** within ATMP, between 2009-2024



Publications per capita 2023 (per million inhabitants)

Note: *EU10 covers Scandinavia and top 6 countries in Europe. **Publications can cover multiple topics and have collaborating authors in multiple countries – sum of total publications will not be equivalent to topic / country total. For searches boolean search string was used, see details in appendix.
Source: Web of Science




ATMP Sweden




triathlon

Unlike for full EU10*, the number of ATMP related publications continue to increase in Sweden

Number of ATMP related publications** from Sweden affiliated sources (2009-2023)



Total publications** of ATMP in Sweden and the different types (2009-2023)



Note: *EU10 covers Scandinavia and top 6 countries in Europe. **Publications can cover multiple topics – sum of total publications will not be equivalent to total for all topics individually. For searches boolean search string was used, see details in appendix.
Source: Web of Science

Content

1. ATMP landscape overview and developments
2. Company landscape
3. Research and publications
4. ATMP in healthcare
5. Clinical trials and horizon scanning
6. Job opportunity analysis
7. Appendix

ATMP in Healthcare

Selected highlights

- 4 ATMP centers have been established at four of the seven university hospitals in Sweden located in Gothenburg, Lund, Stockholm and Uppsala
- 7 approved and NT-recommended ATMP therapies available in Sweden, where 4 are CAR-T therapies and 3 are gene therapies
- 146 CAR-T infusions given to patients as standard of care
- 5 ATMPs were approved by EMA in 2022
- 19 out of 26 of EMA approved therapies are gene therapies
- The timeline from EMA approval to NT-rådet first indication recommendation varies, with a seen minimal length of 8 months
- 6 EMA approved ATMPs are currently under investigation by TLV and NT-rådet




Current ATMP healthcare in Sweden

Nation-wide on approved ATMPs

- 7** approved therapies recommended by NT-rådet
- Zolgensma
 - Luxturna
 - Yescarta
 - Kymriah
 - Tecartus
 - Libmeldy
 - Breyzani
- 146** CAR-T infusions*
- 8** Luxturna treatments
- 9** Zolgensma patients
- 1** Libmeldy patient

Hospitals providing treatment

- 7** Hospitals providing treatments
- 4** Active ATMP centers



Note: CAR-T numbers as those reported as standard of care according to SweCarnet, assuming 1 infusion per patient + 5 Re-infusions. Reported number of treatments outside CAR-T infusions are from April 2024
 Source: Triathlon analysis, SWECARNET, CAR-T treatments May 2024 ([link](#)), other treatment data based on presentation on ATMP treatment held in April 2024

Sweden now has 4 ATMP centers, creating a strong infrastructure to support ATMP clinical use

Uppsala University Hospital (Uppsala)

- First in Europe to give CAR-T treatment in May of 2014 → Celebrated 10 year anniversary 13/5
- ATMP centre collaboration between UU, UUH, RU. Inaugurated sept 2023



Karolinska ATMP Center (Stockholm)

- Vecura facility - GMP manufacturing of 50+ different ATMP products for more than 800 patients in clinical trials since 1996
- The first pre-GMP facility in the Nordics inaugurated 2019



Sahlgrenska University Hospital (Gothenburg)

- ATMP Center created in 2020, including Center for Cell- and Gene Therapies from 2024
- GMP manufacturing of 3 ATMP products for approx. 2200 patients since 1987, with tissue establishment for start materials




Skåne University Hospital (Lund)

- LU-ATMP, university linked ATMP center inaugurated June 2023
- Lund Stem Cell Center




The time from EMA approval to NT-rådet recommendation varies between 8-48 months

○ EMA approval
 ○ NT-rådet first indication recommendation




Note: Date for NT-rådet first recommendation regards the first indication that the therapy was recommended for
 Source: Triathlon analysis, EMA, CAT Quarterly highlights and approved ATMPs January 2024 ([link](#)), Janusinfo.se

EMA approved ATMPs have expanded over the last six years, with 17 approvals between 2018 to 2024



Six therapies recently approved by EMA are under investigation or have planned assessment by NT-rådet

○ EMA approval ✕ NT-rådet non-recommendation



Note: 4 therapies approved by EMA before 2018 not included since it is not available in Sweden, or because the company has decided not to market the therapy in Sweden
 Source: Triathlon analysis, EMA, CAT Quarterly highlights and approved ATMPs January 2024 ([link](#)), Janusinfo.se



Content

1. ATMP landscape overview and developments
2. Company landscape
3. Research and publications
4. ATMP in healthcare
5. Clinical trials and horizon scanning
6. Job opportunity analysis
7. Appendix

Clinical trials and horizon scanning


Selected highlights

- Currently 48 active clinical ATMP trials via the ATMP centers in Sweden, with 9 new clinical trials initiated in 2023
- Swedish companies have 60 ongoing ATMP projects, where 58% are in the preclinical phase
- 33 out of 44 ATMP classified clinical trials are GTMP
- 1 751 active ATMP clinical trials globally, with 43% in Phase I
- Over 400 industrial clinical ATMP trials initiated in 2023 globally, +300% compared to 2013
- China has grown from close to no studies in 2008 to >40% of all industrial clinical ATMP trial sites in 2023
- 99 ATMPs are in clinical phase III globally
- At least 6 ATMPs are in the final stages of the drug pipeline for approval in EU




In total, there are currently 48 active clinical ATMP trials via the ATMP centers in Sweden

Clinical ATMP trials per phase



ATMP classes of active clinical ATMP trials




Note: Includes all active clinical trials, not only by Swedish companies. Graph including 47 trials in status follow up and recruiting. 1 study from Intellia Therapeutics had no clinical phase registered in data. Only 44 studies had ATMP class reported
Source: Triathlon analysis based on clinical trials data received in September 2024 from ATMPSweden ([link](#)).

Development of clinical ATMP trials in Sweden

Cumulative # started clinical ATMP trials in Sweden 2006 to 2024*


Based on start year for currently active trials




Note: *2024 as per 18th of September. Studies categorized as only FIH in data sorted as phase I. Study from Intellia Therapeutics with no provided clinical phase in data.
Source: Triathlon analysis based on clinical trials data received from ATMP centres on [ATMPSweden.se](https://atmpsweden.se) ([link](#)).

As of March 2023, Swedish companies had 60 ongoing ATMP projects, with majority in the preclinical phase

Ongoing Swedish ATMP projects as of March 2023, divided by therapy




Ongoing Swedish ATMP projects as of March 2023, divided by phase




Note: Only includes projects from Swedish companies (Astra Zeneca not included)
Source: The Swedish drug discovery & development pipeline 2023, SwedenBIO

Global clinical ATMP trials are growing, with about +300% industrial trial starts in 2023 compared to 2013


Clinical ATMP trials per phase



Sites of industrial clinical ATMP trials (2008-2023)*



Started industrial clinical ATMP trials*




Note: *Not including tissue engineering in this categorization

Source: Triathlon analysis based on clinical trials data from ARM sector report (Q1 2024, [link](#)), Graph data of started trials and site division from IQVIA Cell and Gene report (2023)

Horizon scan: On the verge of contributing to available therapies for patients, nearly 100 ATMPs are in late clinical stage globally

Indications for global clinical phase 3 trials



Examples of therapies in final stages of the drug pipeline for 2024

| Therapy | Developer | Indication | Status |
|---------------------------|------------------------|----------------------------------------|-----------------------------------------------|
| Casgevy | Vertex Pharmaceuticals | beta-Thalassemia Anemia, Sickle Cell | Feb 13 2024: Approved in the EU |
| BEQVEZ | Pfizer | Hemophilia B | 2024 decision possible in the EU |
| Vyjuvek | Krystal Biotech | dystrophic epidermolysis bullosa (DEB) | 2024 EU approval decision possible in H2 2024 |
| RP-L102 | Rocket Pharma | Fanconi Anemia | 2024 decision possible in EU |
| Elevidys | Sarepta therapeutics | Duchenne muscular dystrophy (DMD) | 2024 EMA MAA submission possible |
| Giroctogene fitelparvovec | Pfizer & Sangamo | Hemophilia A | EMA MAA submissions possible in 2024 |

Content

1. ATMP landscape overview and developments
2. Company landscape
3. Research and publications
4. ATMP in healthcare
5. Clinical trials and horizon scanning
6. Job opportunity analysis
7. Appendix

Job opportunity analysis


Selected highlights

- 700+ identified ATMP job postings in Nordics 2020-2024
- With 519 job postings, Denmark takes the lead in the Nordics, followed by Sweden with 156 postings between 2020 to May 2024
- Novo Nordisk is the main employer with 362 job postings, Astra Zeneca follows with 97 postings
- Swedish job postings are dominated by jobs in Gothenburg with 60% out of all jobs
- Astra Zeneca has 60% of all ATMP job postings in Sweden



Denmark and Novo Nordisk AS leads job postings in the Nordic countries (2020-2024*)

Total job posting count for Nordic countries (2020-2024*)




Top 10 organizations, in # of job postings

| Organization | # Job postings |
|------------------------------------------|----------------|
| Novo Nordisk AS | 362 |
| AstraZeneca Plc | 97 |
| Fujifilm Diosynth Biotechnologies Uk Ltd | 68 |
| Bristol-Myers Squibb Co | 30 |
| Ferring Pharmaceuticals SA | 30 |
| AGC Biologics Inc | 27 |
| Gilead Sciences Inc | 17 |
| Hansa Biopharma AB | 16 |
| PPD Inc | 8 |
| Novartis AG | 7 |

Note: *Data for 2024 is retrieved from 1st of January 2024 to 4th of May 2024
 Source: Triathlon analysis based on data from GlobalData, details can be found in appendix

A majority of Swedish ATMP job postings were found in Gothenburg, with Astra Zeneca as a main employer

Job posting division of cities in Sweden



Division of job postings per organization (2021-2024*)

| Organization | # Job postings |
|-----------------------------------------------|----------------|
| AstraZeneca Plc | 94 |
| Hansa Biopharma AB | 16 |
| Bristol-Myers Squibb Co | 13 |
| ProPharma Group Holdings LLC | 7 |
| Eurofins Scientific SE | 5 |
| Gilead Sciences Inc | 5 |
| Parexel International Corp | 5 |
| Johnson & Johnson | 3 |
| Novartis AG | 3 |
| GSK / MaxCyte / Pfizer/ PPD/ PTC Therapeutics | 1 / company |

Note: Data is retrieved from 1st of January 2020 to 4th of May 2024
 Source: Triathlon analysis based on data from GlobalData, details can be found in appendix

Content

1. ATMP landscape overview and developments
2. Company landscape
3. Research and publications
4. ATMP in healthcare
5. Clinical trials and horizon scanning
6. Job opportunity analysis
7. Appendix

Glossary

- **ATMP:** Advanced Therapy Medicinal Products, including Gene therapy, Cell therapy and Tissue engineering
- **CAR-T Therapy:** Chimeric Antigen Receptor T-cell therapy; immunotherapy that modifies a patient's T-cells to target & destroy cancer cells
- **cATMP:** Combined Advanced Therapy Medicinal Product. Medicinal product incorporating an advanced therapy medicinal product (ATMP) plus one or more medical devices as an integral part of the product
- **Cell therapy:** Addition of healthy cells to replace disease/damaged cells in the patient
- **CMO:** Contract Manufacture Organization
- **Combined product:** See cATMP
- **CRO:** Contract Research Organization
- **EISMEA:** European Innovation Council and SMEs Executive Agency
- **EMA:** European Medicines Agency
- **EU10:** In this report Germany, UK, France, Spain, Italy, Netherlands and the Nordics
- **Ex vivo:** Occurring outside a living organism
- **Gene therapy:** Technique to deliver recombinant nucleic acids, typically an entire gene, into cells in order to modify gene expression with the aim of treating or preventing disease
- **GTMP:** Type of advanced therapy medicinal product (ATMP) containing an active substance consisting of or containing a recombinant nucleic acid, which is administered as a gene therapy for therapeutic, prophylactic or diagnostic purposes
- **In vivo:** Within the normal biological context of a living organism
- **NT-rådet:** An expert group with hospital-regional representation that is part of the collaborative model for medicines. Decides which medicines should be included in the national process for orderly introduction and has a mandate from the regions to make recommendations on the use of these medicines
- **Regenerative medicine:** Medical approaches aimed to repair, replace or regenerating damaged tissue, including cell therapy, gene therapy, tissue engineering, organ transplants etc
- **sCTMP:** Somatic cell therapy see cell therapy medicinal product
- **SME:** Small and medium-sized enterprises
- **Tissue engineering:** An array of techniques used to create artificial organs for transplantation into the body to repair or improve bodily functions
- **TEP:** Tissue Engineered Product. A medicine containing engineered cells or tissues, which is intended to regenerate, repair or replace a human tissue

Search strategy – Business Retriever

To analyze development of Swedish ATMP Developers, Business Retriever was used to retrieve data from annual reports via allabolag.se.

Since the annual reports of 2023 was not released for most of the chosen companies during the time for retrieving data, 2022 was given as the final year.

Data extraction method

- Identified ATMP SME developers
- ID numbers for companies identified
- Data download to Excel of annual reports 2018-2022 via business retriever based on ID numbers
- Data was managed based on download
- Data was crosschecked with annual reports on allabolag.se and company websites in cases where annual reports were missing

The Business Retriever database was accessed 2024-04-23

Search strategy – WebOfScience

The general search strategy and search terms have been kept similar to previous reports with smaller corrections in order to provide comparable results to previous ATMP Sweden reports. Due to more details provided in the Web of Science data, this database was used (instead of PubMed as in previous reports).

The strategy aims to include three ATMP types:

- Gene therapy medicines
- Somatic-cell therapy medicines & Tissue engineered products
- Tissue-engineered medicines.

Web of Science strategy for published research within advanced therapies

- **Gene therapy medicinal product (GTMP):**
"gene therapy" (Topic) or "genetic therapy" (Topic) or "GTMP" (Topic)
- **Somatic-cell therapy medicinal product (sCTMP) & Tissue engineered product (TEP):**
"cell therapy" (Topic) or "cell-based therapy" (Topic) or "somatic cell therapy" (Topic) or "tissue engineered product"
- **Chimeric Antigen Receptor (CAR) T-Cell therapy:**
"CAR-T" (Topic) or "CAR T-cell therapy" (Topic) or "chimeric antigen receptor T-cell therapy" (Topic)
- **Clinical trials:**
"clinical trial" (Topic)

Web of Science strategy for countries

The following countries were included for separate analysis:

- Sweden
- Norway
- Finland
- Denmark
- United Kingdom (including England, Wales, Scotland, Northern Ireland)
- Germany
- The Netherlands
- Italy
- Spain
- France

The countries included were the same countries included in previous reports and were originally selected by RISE. France has been added due to a high activity

The published research per country was found by searching country per country.

The searches were filtered for type of article and publication dates between 2009-12-31 and 2024-12-31.

Web of Science was accessed 2024-06-12

Search strategy – EISMEA Swedish SMEs

Data sources utilized

- [European Innovation Ecosystems datahub \(eisma.eu\)](#)
- [Horizon 2020 INNOSUP data hub \(eisma.eu\)](#)
- [COSME data hub \(eisma.eu\)](#)
- [EIC Pathfinder data hub \(eisma.eu\)](#)
- [EIC Accelerator data hub \(eisma.eu\)](#)
- [EIC Fast Track to Innovation data hub \(eisma.eu\)](#)
- [EU Funding and Tenders Portal**](#)

The projects were filtered by searching for the Swedish SMEs*

- CombiGene
- asgard
- Ilya
- Sinfonia
- Verigrift
- Elicera
- Mendus
- NEOGAP
- Lipigon
- Cline
- Amniotics
- TIKOMED
- Cell4Cure
- Xintela
- Lokon
- Alder
- NextCell
- Anocca
- ProCella
- Cellavos
- SeqCure
- Curacell
- Stroma
- XNK
- CarryGenes

* Full company names were not used to avoid irrelevant search results for terms such as “therapeutics” for the datahubs. For EU Funding and Tenders portal, full company names were used.

EISMEA search method

- All Sweden ATMP SME developer companies was searched for in each respective database using the noted search terms
- Results where the Sweden ATMP SME developer companies received funding were compiled into a single common list
- The projects start and end year was noted together with funding received by the project (EU contribution)

The databases were accessed 2024-06-27

**Accessed 2024-10-22

Search strategy – Global Data database

The following search criteria were used

- Focus on Nordic countries (Sweden, Norway, Finland, Denmark, Iceland)
- Regenerative Medicine - Job Postings; AND
- Job Postings with "cell therapy", "gene therapy", "ATMP", "advanced therapy medicinal products", "tissue engineering" in Description
- Date Range: 1 Jan-2021 till 4-May-2024
- It was noted in the quote from Global Data that data was limited for small biotech companies

Data received from Global Data consisted of the following data

- Job ID
- Posted
- Closed
- Title
- Company
- City
- Country
- Seniority
- Theme
- Soft Skills
- Technical Skills
- Education Stream
- Occupation
- Min Salary(USD)
- Max Salary(USD)
- Salary(LCU)
- Min Salary(LCU)
- Max Salary(LCU)
- Job Descriptions

Data extraction method

- Retrieved data was checked to see if postings were relevant to ATMP; Out of 52 checked postings, 9 were marked as unclear, giving an approximate uncertainty of 20%
- Based on data, graphs were created to visualize retrieved input

Most of companies in the Global Data database job postings were international pharma companies. In the data, it was stated that SME companies were not